SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (225)10/28/2008 1:22:16 AM
From: Ian@SI  Respond to of 269
 
Jim,

You're probably right.

It seemed to me that no deaths is a very good thing.
What I don't know is what the expected death rate would be for 122 hospitalized flu victims. Nor is it likely that a Ph II would be powered to show stat sig.

122 complete recoveries with no reported AEs struck me as being worth at least $0.03. :-)

Ian.



To: IRWIN JAMES FRANKEL who wrote (225)10/28/2008 9:17:10 AM
From: rkrw  Read Replies (1) | Respond to of 269
 
This makes me think numerically it may have pointed toward Tamiflu:

<<There were no statistically significant differences in any of the efficacy endpoints between the three treatment arms.>>>


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News